July 02, 2003
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Trial of anti-scarring agent for glaucoma surgery under way
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
A clinical trial of an agent meant to improve the outcome of glaucoma filtering surgery by preventing scarring has completed enrollment of phases 2 and 3 in Europe, according to Cambridge Antibody Technology, the drug’s developer.
Trabio, a human monoclonal antibody formerly known as CAT-152, is being tested in six countries. In the trial, 344 patients undergoing first-time trabeculectomy have been enrolled. Recruitment is ongoing for a similar trial in the United States.
According to the company, up to 250,000 patients per year undergoing glaucoma surgery in the United States and Europe might benefit from treatment with Trabio.